

# Michal Mielcarek

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7121072/publications.pdf>

Version: 2024-02-01

35  
papers

1,381  
citations

361045

20  
h-index

395343

33  
g-index

36  
all docs

36  
docs citations

36  
times ranked

1778  
citing authors

#	ARTICLE	IF	CITATIONS
1	Structural Abnormalities of the Optic Nerve and Retina in Huntington's Disease Pre-Clinical and Clinical Settings. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5450.	1.8	6
2	Identification of the Transcriptional Biomarkers Panel Linked to Pathological Remodelling of the Eye Tissues in Various HD Mouse Models. <i>Cells</i> , 2022, 11, 1675.	1.8	2
3	Polyglutamine diseases: looking beyond the neurodegenerative universe. <i>Neural Regeneration Research</i> , 2021, 16, 1186.	1.6	3
4	Kinetin stimulates differentiation of C2C12 myoblasts. <i>PLoS ONE</i> , 2021, 16, e0258419.	1.1	5
5	Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings. <i>Frontiers in Medicine</i> , 2021, 8, 809118.	1.2	91
6	Cross-Sectional Transcriptional Analysis of the Aging Murine Heart. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 565530.	1.6	5
7	Prevalence of Non-psychiatric Comorbidities in Pre-symptomatic and Symptomatic Huntington's Disease Gene Carriers in Poland. <i>Frontiers in Medicine</i> , 2020, 7, 79.	1.2	12
8	A35...An altered metabolism of nucleotides leads to huntington's disease related cardiomyopathy. , 2018, , ,		0
9	Neuro-Cardio Mechanisms in Huntington's Disease and Other Neurodegenerative Disorders. <i>Frontiers in Physiology</i> , 2018, 9, 559.	1.3	40
10	Transcriptional Signature of an Altered Purine Metabolism in the Skeletal Muscle of a Huntington's Disease Mouse Model. <i>Frontiers in Physiology</i> , 2017, 8, 127.	1.3	22
11	Early transcriptional alteration of histone deacetylases in a murine model of doxorubicin-induced cardiomyopathy. <i>PLoS ONE</i> , 2017, 12, e0180571.	1.1	18
12	Oxidized low-density lipoproteins enhance expression and activity of CD39 and CD73 in the human aortic valve endothelium. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2016, 35, 713-719.	0.4	6
13	Changes in cardiac nucleotide metabolism in Huntington's disease. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2016, 35, 707-712.	0.4	13
14	Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. <i>Molecular Neurodegeneration</i> , 2016, 11, 64.	4.4	46
15	An impaired metabolism of nucleotides underpins a novel mechanism of cardiac remodeling leading to Huntington's disease related cardiomyopathy. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 2147-2157.	1.8	42
16	A shared mechanism of muscle wasting in cancer and Huntington's disease. <i>Clinical and Translational Medicine</i> , 2015, 4, 34.	1.7	22
17	HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 42.	1.8	90
18	Update on Huntington's disease: Advances in care and emerging therapeutic options. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 169-178.	1.1	61

#	ARTICLE	IF	CITATIONS
19	HDAC4-Myogenin Axis As an Important Marker of HD-Related Skeletal Muscle Atrophy. <i>PLoS Genetics</i> , 2015, 11, e1005021.	1.5	56
20	Huntington's disease is a multi-system disorder. <i>Rare Diseases (Austin, Tex )</i> , 2015, 3, e1058464.	1.8	42
21	Dysfunction of the CNS-Heart Axis in Mouse Models of Huntington's Disease. <i>PLoS Genetics</i> , 2014, 10, e1004550.	1.5	83
22	Skeletal muscle pathology in Huntington's disease. <i>Frontiers in Physiology</i> , 2014, 5, 380.	1.3	91
23	B44 The Cns-heart Axis Is A Source Of Cardiac Dysfunction In Mouse Models Of Huntington's Disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, A24-A24.	0.9	0
24	M09 Myostatin Inhibition as a Novel Approach to Targeting Muscle Pathology in HD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, A97-A97.	0.9	7
25	The Huntington's Disease-Related Cardiomyopathy Prevents a Hypertrophic Response in the R6/2 Mouse Model. <i>PLoS ONE</i> , 2014, 9, e108961.	1.1	29
26	HDAC4 Reduction: A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration. <i>PLoS Biology</i> , 2013, 11, e1001717.	2.6	143
27	HDAC4 Does Not Act as a Protein Deacetylase in the Postnatal Murine Brain In Vivo. <i>PLoS ONE</i> , 2013, 8, e80849.	1.1	30
28	A12 HDAC4 interacts with huntingtin and HDAC4 reduction decreases cytoplasmic aggregation and rescues synaptic dysfunction in HD mouse models. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, A4.1-A4.	0.9	0
29	SAHA Decreases HDAC 2 and 4 Levels In Vivo and Improves Molecular Phenotypes in the R6/2 Mouse Model of Huntington's Disease. <i>PLoS ONE</i> , 2011, 6, e27746.	1.1	137
30	VITO-2, a new SID domain protein, is expressed in the myogenic lineage during early mouse embryonic development. <i>Gene Expression Patterns</i> , 2009, 9, 129-137.	0.3	28
31	Genetic Knock-Down of HDAC7 Does Not Ameliorate Disease Pathogenesis in the R6/2 Mouse Model of Huntington's Disease. <i>PLoS ONE</i> , 2009, 4, e5747.	1.1	61
32	VITO-1 is an essential cofactor of TEF1-dependent muscle-specific gene regulation. <i>Nucleic Acids Research</i> , 2004, 32, 791-802.	6.5	59
33	Native transfer RNA catalyzes Diels-Alder reaction. <i>Biochemical and Biophysical Research Communications</i> , 2002, 294, 145-148.	1.0	11
34	VITO-1, a novel vestigial related protein is predominantly expressed in the skeletal muscle lineage. <i>Mechanisms of Development</i> , 2002, 119, S269-S274.	1.7	52
35	Identification of 6-Furfuryladenine (Kinetin) in Human Urine. <i>Biochemical and Biophysical Research Communications</i> , 2000, 279, 69-73.	1.0	48